Needham & Co Downgrades Anesiva (ANSV) to Hold
More News related to ANSV
- Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing
- Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger
- Anesiva Receives Nasdaq Listing Compliance Notice
- Needham & Co Downgrades Anesiva (ANSV) to Hold
- Anesiva (ANSV) Announces FDA Approval of sNDA to Expand Zingo(TM) Indication to Include Adults
More News related to Downgrades
- Kinross Gold (KGC) Receives Authorization to Re-Commence Exploration on Project in Ecuador
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Stryker (SYK) Announces Two Acquisitions
- Adobe (ADBE) Cutting 680 Full-Time Jobs to Align Costs with '10 Operating Plan
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
Needham & Co downgrades Anesiva (Nasdaq: ANSV) from Buy to Hold.
Anesiva, Inc. (Anesiva) is a biopharmaceutical company focused on the development and commercialization of therapeutic treatments for pain management.
Related Categories
DowngradesStocks Mentioned
-0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
